A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples